Most researchers searching for CJC-1295 in Panic immediately realize that local retail options are nearly impossible to find. This online-only market structure is a genuine benefit for researchers — top vendors compete on lab-verified purity in ways brick-and-mortar outlets simply cannot. What reliably differentiates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety documentation. This guide gives Panic researchers the practical tools to verify sourcing options methodically and source research-grade CJC-1295 with confidence.
CJC-1295: What the Research Shows
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Panic studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
CJC-1295 Purchasing Guide
The most consistent path to quality CJC-1295 is community research first — peptide forums track vendor quality over time that are more trustworthy than marketing materials. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone does not confirm what the compound actually is. Negative indicators in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, unclear production details, no community presence, and COAs that lack endotoxin data. Bacteriostatic water is the standard reconstitution medium for CJC-1295 — it contains 0.9% benzyl alcohol that inhibits bacterial growth and extends reconstituted shelf life to 30 days refrigerated.
Order CJC-1295 — ships to Panic
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; do not freeze and thaw reconstituted CJC-1295 multiple times by preparing small aliquots before storage. Bacterial endotoxin contamination is the primary safety concern unique to this class of compound — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. Researchers running multi-compound protocols with CJC-1295 should examine published studies for potential interaction data before proceeding with any multi-compound protocol.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
